Aimmune Therapeutics

Aimmune Therapeutics, a subsidiary of Nestlé Health Science, develops pharmaceutical therapies for food, gastrointestinal, and metabolic-related diseases, with products like PALFORZIA, ZENPEP, and VOWST.

Services

Aimmune Therapeutics develops pharmaceutical therapies to prevent, manage, and treat food, gastrointestinal (GI), and metabolic-related diseases. The company's focus is on creating innovative medicines for diseases that currently have few or no treatment options. By offering specialized therapies, Aimmune addresses unmet medical needs in these specific health domains.

Global Operations

Aimmune Therapeutics operates in multiple countries, including the United States, Germany, United Kingdom, Ireland, Switzerland, Austria, and France. This international presence allows the company to extend its reach and impact across different healthcare markets, enabling access to its therapies for a broader patient population.

Part of Nestlé Health Science

Aimmune Therapeutics is part of Nestlé Health Science, a global leader in the field of nutritional science. This affiliation supports Aimmune's mission to develop and provide innovative medicines for conditions with limited treatment options, leveraging Nestlé's extensive resources and expertise in health and science.

Therapies and Products

Aimmune Therapeutics offers several key therapies such as PALFORZIA for the treatment of food allergies, ZENPEP for managing exocrine pancreatic insufficiency, and VOWST for unspecified treatments. These products are part of the company's robust pipeline designed to address critical needs in food, gastrointestinal (GI), and metabolic-related diseases.

Ethical Practices and Compliance

Committed to ethical practices, Aimmune Therapeutics maintains a comprehensive compliance program in accordance with the California Health and Safety Code §119400-119402. This ensures that the company's operations meet regulatory standards and uphold the highest levels of integrity in their methodologies.